文献速递乳腺癌

评估哌柏西利联合来曲唑作为雌激素受体阳性早期乳腺癌新辅助治疗的随机II期研究:PALLET试验

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
PubMed 文献 · J Clin Oncol · 2018-12-06

PALLET是一项II期随机试验,评估哌柏西利联合来曲唑作为新辅助治疗的效果。307例绝经后ER阳性原发性乳腺癌患者随机接受来曲唑单药或联合哌柏西利治疗14周。联合治疗显著增强Ki-67抑制(中位对数倍数变化-4.1 vs -2.2,P<.001),但临床缓解率无显著差异(54.3% vs 49.5%,P=.20)。

要点

  • 哌柏西利联合来曲唑较来曲唑单药显著增强Ki-67抑制(中位对数倍数变化-4.1 vs -2.2,P<.001)。
  • 联合治疗组完全细胞周期停滞率更高(90% vs 59%,P<.001)。
  • 联合治疗未显著提高临床缓解率(54.3% vs 49.5%,P=.20),可能与凋亡减少有关。

核心结论

  • 在ER阳性原发性乳腺癌中,来曲唑加用哌柏西利显著增强恶性细胞增殖(Ki-67)的抑制,但14周内未提高临床缓解率,可能与同时存在的凋亡减少有关。

研究设计与样本

  • PALLET是一项II期随机试验,纳入307例绝经后ER阳性原发性乳腺癌且肿瘤≥2.0 cm的患者,按3:2:2:2随机分配至四组:A组来曲唑2.5 mg/d治疗14周;B组来曲唑2周后哌柏西利联合来曲唑至14周;C组哌柏西利2周后哌柏西利联合来曲唑至14周;D组哌柏西利联合来曲唑治疗14周。哌柏西利125 mg/d口服,21天用药、7天停药。基线及第2、14周行粗针穿刺活检。共同主要终点为来曲唑组(A)与哌柏西利联合来曲唑组(B+C+D)基线至14周Ki-67变化及14周后临床缓解(序数和超声)。完全细胞周期停滞定义为Ki-67≤2.7%。凋亡以cleaved poly (ADP-ribose) polymerase表征。

主要发现

  • 哌柏西利联合来曲唑组与来曲唑组临床缓解(完全缓解+部分缓解)分别为54.3%与49.5%,差异无统计学显著(P=.20);疾病进展分别为3.2%与5.4%。
  • 在190例可评估患者(61.9%)中,哌柏西利联合来曲唑组Ki-67中位对数倍数变化大于来曲唑组(-4.1 vs -2.2,P<.001),几何平均变化分别为-97.4%与-88.5%。
  • 哌柏西利联合来曲唑组达到完全细胞周期停滞的患者更多(90% vs 59%,P<.001)。
  • 哌柏西利联合来曲唑组cleaved poly (ADP-ribose) polymerase中位对数倍数变化(抑制)大于来曲唑组(-0.80 vs -0.42,P<.001)。
  • 哌柏西利联合来曲唑组3级或以上毒性发生率更高(49.8% vs 17.0%,P<.001),主要由于无症状性中性粒细胞减少。

关键数值与推荐

  • 完全细胞周期停滞定义为Ki-67≤2.7%。
  • 哌柏西利125 mg/d口服,21天用药、7天停药。
  • 来曲唑2.5 mg/d治疗14周。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination palbociclib plus letrozole as neoadjuvant therapy. PATIENTS AND METHODS: Postmenopausal women with ER-positive primary BC and tumors greater than or equal to 2.0 cm were randomly assigned 3:2:2:2 to letrozole (2.5 mg/d) for 14 weeks (A); letrozole for 2 weeks, then palbociclib plus letrozole to 14 weeks (B); palbociclib for 2 weeks, then palbociclib plus letrozole to 14 weeks (C); or palbociclib plus letrozole for 14 weeks. Palbociclib 125 mg/d was administered orally on a 21-days-on, 7-days-off schedule. Core-cut biopsies were taken at baseline and 2 and 14 weeks. Coprimary end points for letrozole versus palbociclib plus letrozole groups (A v B + C + D) were change in Ki-67 (protein encoded by the MKI67 gene; immunohistochemistry) between baseline and 14 weeks and clinical response (ordinal and ultrasound) after 14 weeks. Complete cell-cycle arrest was defined as Ki-67 less than or equal to 2.7%. Apoptosis was characterized by cleaved poly (ADP-ribose) polymerase. RESULTS: Three hundred seven patients were recruited. Clinical response was not significantly different between palbociclib plus letrozole and letrozole groups ( P = .20; complete response + partial response, 54.3% v 49.5%), and progressive disease was 3.2% versus 5.4%, respectively. Median log-fold change in Ki-67 was greater with palbociclib plus letrozole compared with letrozole (-4.1 v -2.2; P < .001) in the 190 evaluable patients (61.9%), corresponding to a geometric mean change of -97.4% versus -88.5%. More patients on palbociclib plus letrozole achieved complete cell-cycle arrest (90% v 59%; P < .001). Median log-fold change (suppression) of cleaved poly (ADP-ribose) polymerase was greater with palbociclib plus letrozole versus letrozole (-0.80 v -0.42; P < .001). More patients had grade 3 or greater toxicity on palbociclib plus letrozole (49.8% v 17.0%; P < .001) mainly because of asymptomatic neutropenia. CONCLUSION: Adding palbociclib to letrozole significantly enhanced the suppression of malignant cell proliferation (Ki-67) in primary ER-positive BC, but did not increase the clinical response rate over 14 weeks, which was possibly related to a concurrent reduction in apoptosis.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Johnston S, Puhalla S, Wheatley D, et al. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. J Clin Oncol. 2018. PMID: 30523750. doi:10.1200/JCO.18.01624

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。